ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Hematologic Cancer
Lymphoma
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Durham, NC, USA:

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than...

Enrolling
Multiple Myeloma
Cancer
Drug: Isatuximab
Drug: Dexamethasone

Phase 2

UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center

Durham, North Carolina, United States and 2 other locations

This study is designed as a phase I-II, open label, dose finding study.Study treatment will be as follows, in 28 day cycles:* Pomalidomide: once dail...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Bendamustine

Phase 1, Phase 2

Cristina Gasparetto

Durham, North Carolina, United States

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

AbbVie
AbbVie

Durham, North Carolina, United States and 40 other locations

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Carfilzomib

Phase 2

AbbVie
AbbVie

Durham, North Carolina, United States and 31 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Durham, North Carolina, United States and 59 other locations

phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma...

Enrolling
Multiple Myeloma
Drug: Selinexor
Drug: Mezigdomide

Phase 1, Phase 2

Karyopharm Therapeutics
Karyopharm Therapeutics

Durham, North Carolina, United States and 24 other locations

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants wi ...

Enrolling
Relapsed/Refractory Multiple Myeloma
Drug: ISB 2001

Phase 1

Ichnos Sciences

Chapel Hill, North Carolina, United States and 6 other locations

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bisp...

Active, not recruiting
Multiple Myeloma
Drug: TNB-383B

Phase 1, Phase 2

TeneoOne

Chapel Hill, North Carolina, United States and 13 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Durham, North Carolina, United States and 126 other locations

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...

Enrolling
Multiple Myeloma
Drug: ABBV-383

Phase 1

TeneoOne

Chapel Hill, North Carolina, United States and 32 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems